BioStock: Status report Coegin Pharma – A new approach to cancer therapy

Nordic biotech Coegin Pharma is responding to calls for new, innovative cancer therapeutics by offering a novel approach through inhibition of a well-validated target, the cPLA₂α enzyme. Since October 2020, the company has been listed on NGM Nordic SME, and, with an experienced board and management team, Coegin Pharma is executing on its new strategic focus on cancer treatments. BioStock has now published a status report of the company, which can be downloaded below.

Read the full status report on Coegin Pharma at biostock.se:

https://www.biostock.se/en/status-report-coegin-pharma-a-new-approach-to-cancer-therapy/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/